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Abstract 
IMPACT OF KRAS/NRAS MUTATIONAL HETEROGENEITY ON CLINICAL 
OUTCOMES IN COLORECTAL CANCER 
  
Jonathan Michael Loree, MD 
 
Advisory Professor: Scott Kopetz, MD, PhD  
 
 
 
Introduction: Mutations in KRAS/NRAS (RAS) predict a lack of benefit from anti-EGFR agents 
in metastatic colorectal cancer (mCRC). As next generation sequencing (NGS) has advanced, 
we are discovering atypical and low allele frequency mutations. We aimed to evaluate how 
NGS can optimally define RAS mutant CRC and the role of relative mutant allele frequency 
(rMAF) as a biomarker. 
Methods: Using institutional and public cohorts of mCRC patients with NGS results, we 
described the prevalence and clinical impact of atypical (not in current guidelines) and low 
rMAF RAS mutations (<50%). rMAF was defined by dividing RAS MAF by the MAF of the 
mutated gene with the highest allele frequency to normalize for tumor content. Functional 
annotation of 113 RAS mutations was performed and functionality of mutations was compared 
to rMAF.  
Results: RAS mutations were noted in 4244/8609 patients (49.3%), with atypical mutations in 
1.3% of patients. The most prevalent atypical mutations were KRAS Q22K (0.2%), KRAS D33E 
(0.1%) and KRAS T50I (0.1%). Of 113 functionally characterized RAS mutations, all 23 non-
activating mutations were atypical, while every guideline cited mutation was activating. Atypical 
variants (HR 2.45, P=0.0092) and those that resulted in MAPK activity greater than KRAS exon 
2 (HR 1.40, P=0.028) had a worse OS. A RAS rMAF >50% was associated with worse OS than 
rMAF <50% in one of two cohorts (P= 0.075 & P=0.0058) and having any RAS mutation was 
vii 
 
associated with a worse OS than wild-type patients. The rMAF of any mutated gene was also 
associated with functional significance in a clinically annotated database, yet the magnitude of 
difference in rMAF was not sufficient to warrant clinical utility in tissue cohorts. However, a 
cfDNA cohort did show striking results demonstrating rMAF was associated with a variants 
functional characterization. 
Conclusions: Through a comprehensive atlas of RAS functional characterization, we show 
that several atypical variants appear clinically relevant. Although rMAF was not useful in 
characterizing variants as damaging, our findings that RAS rMAF is associated with prognosis 
suggests allele frequency may be useful information in standard clinical reports.  
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Chapter 1: Introduction 
Colorectal Cancer 
Colorectal Cancer (CRC) is the third leading cause of cancer for both men and women in the 
United States, resulting in an estimated 135,430 new cases and 50,260 deaths in 2017.1 
Although surgical resection is curative for many, 21% of patients present with synchronous 
metastases at the time of initial diagnosis and 10-25% of stage II/III patients will recur.2 
Curative intent surgical or ablative maneuvers are options in select cases of oligometastatic 
CRC and result in improved overall survival (OS).3 However, most patients with metastatic 
CRC (mCRC) are not curable and will require systemic therapy. In the first and second line 
setting, this typically consists of a fluoropyrimidine doublet (FOLFOX/CAPOX or 
FOLFIRI/CAPIRI) combined with a biologic agent that either targets angiogenesis 
(bevacizumab, ramicurumab, or ziv-aflibercept), or the epidermal growth factor receptor 
(EGFR) (panitumumab or cetuximab) in patients without KRAS/NRAS (RAS) mutations [Figure 
1].4–6 First line FOLFOXIRI +/- bevacizumab can also be considered, particularly in patients 
requiring maximal response or those with aggressive biology.7–9 Subsequent therapeutic 
options in the ≥3rd line setting include anti-EGFR +/- cytotoxics (in RAS wild type patients who 
have not previously progressed on cetuximab or panitumumab), regorafenib, TAS-102 and 
investigational agents.10–13 
 
Though cytotoxic agents represent the backbone of systemic therapy, advances in the 
molecular characterization of mCRC and the advent of targeted therapies are expanding 
treatment options for patients beyond conventional chemotherapy. The recent approvals of 
pembrolizumab and nivolumab in mCRC with microsatellite instability (MSI) or mismatch repair 
deficiency (MMRd) are representative examples of both the successes and challenges of  
 
2 
 
 
 
 
 
 
 
 
Figure 1. Treatment algorithm for microsatellite stable metastatic colorectal cancer. 
Reproduced with permission from: Loree JM, Kopetz S. Recent developments in the treatment 
of metastatic colorectal cancer. Ther Adv Med Oncol. 2017;9(8):551-564.  
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targeted agents in mCRC. Though response rates were 26-40% with anti-PD1 therapy, they 
were largely limited to the ~5% of mCRC patients who have MSI-H tumors.14, 15 Successes 
have been noted in several other small subgroups with molecularly matched therapies. In the 
8-10% of patients with BRAF mutated mCRC, the addition of vemurafenib to irinotecan and 
cetuximab resulted in improved progression free survival (PFS) (HR 0.42, 95% CI 0.26-0.66, 
P<0.001) in SWOG 1406.16 For the 3-4% of ERBB2 amplified mCRC, the HERACLES trial with 
trastuzumab and lapatinib had a 30% response rate (RR) in heavily pre-treated patients, while 
trastuzumab and pertuzumab had a 23% RR in the MyPathway basket study.17, 18 Targeted 
agents represent promising new strategies in treating mCRC, however defining the ideal 
population for each of these treatments is essential to their appropriate inclusion into standard 
of care treatment algorithms. 
 
KRAS/NRAS (RAS) Mutations in Colorectal Cancer 
Alterations in the canonical mitogen-activated protein kinase (MAPK) pathway are key 
determinants of clinical course in mCRC and are present in an estimated 59% of non-
hypermutated CRC and 80% of hypermutated tumors.19 While there is significant cross talk 
between the MAPK-ERK pathway and other signaling cascades, such as the PIK3CA/AKT and 
Wnt pathways, we will focus on the implications of alterations in the MAPK-ERK pathway 
downstream of the epidermal growth factor receptor (EGFR). Alterations in these genes have 
been shown to be associated with resistance to the anti-EGFR agents cetuximab and 
panitumumab. Key proteins involved in this pathway include EGFR, KRAS/NRAS, BRAF, MEK 
1/2, and ERK 1/2. 
 
In a simplified version of this signaling cascade [Figure 2], extracellular ligand binding to growth 
factor receptors, such as the EGFR transmembrane receptor, results in activation of the  
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Figure 2.  Simplified schematic of MAPK signaling in colorectal cancer. 
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cascade. Following activation, these receptors recruit guanine nucleotide exchange factors 
(GEFs) to the plasma membrane where RAS proteins are anchored. The geographic coupling 
of GEFs near RAS results in GEFs catalyzing the exchange of bound GDP for GTP.20 The RAS 
family of proteins are GTPases whose functional status is determined by the phosphorylation 
state of bound guanine. RAS assumes an active state when bound to GTP and is subsequently 
able to activate downstream effectors, such as the RAF family of proteins. BRAF is the 
stereotypical RAF family protein with clinical significance in mCRC. Activated BRAF 
phosphorylates and activates the kinase enzymes MEK1/2 which then phosphorylate ERK1/2. 
Activated ERK1/2 subsequently translocates into the nucleus and causes downstream 
activation of transcription factors and cell cycle progression.  
 
Though alterations are possible at each step in the MAPK-ERK pathway, RAS mutations are 
the most common.21, 22 In early stage disease, the prognostic impact of RAS alterations is 
unclear. While the Alliance NO147 trail showed the strongest evidence that these mutations 
may have prognostic impact, numerous other trials and retrospective studies have not shown 
consistent results.23–25 Following curative intent resection of liver metastases, we have shown 
that RAS mutations are associated with a worse median overall survival (OS) when RAS is 
considered alone (48 vs 71 months, P<0.001) and a worse relapse free survival (RFS) 
following hepatectomy when co-mutated with TP53 (9 vs 11 months, P<0.001).26 In the 
metastatic setting, RAS mutations appear to have a prognostic impact on OS in the era of anti-
EGFR based therapies, however may not have clinical implications independent of these 
therapies.27 In trials assessing the impact of anti-EGFR based therapies with a control arm 
(NCIC CO.17 and 20020408), the OS and PFS point estimates for RAS mutant and RAS wild 
type patients receiving best supportive care appear to overlap, suggesting that these molecular 
alterations are only responsible for altering survival in the setting of targeted therapies.10, 11, 28 
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The major clinical relevance of these variants stems from the fact that RAS mutations are a 
predictive biomarker of a lack of response to anti-EGFR agents. Testing for these mutations 
has become a mandatory companion test prior to treatment with cetuximab or panitumumab 
due to this predictive capacity.10, 29 Identification of patients with these alterations is important 
not only to avoid the potential toxicity and financial implications of ineffective therapy, but RAS 
mutations may also predict harm in the setting of anti-EGFR treatment. In the PRIME study, 
RAS mutant mCRC patients treated with panitumumab + FOLFOX4 had a worse mPFS than 
patients who received FOLFOX4 alone (HR 1.31, 95% CI 1.07-1.60, P=0.008).28, 30  
 
Expanding the Definition of RAS Mutant Metastatic Colorectal Cancer 
Although mutations in KRAS exon 2 were the first noted predictive alterations, extended RAS 
testing to include KRAS/NRAS exon 2 (codon 12 & 13), exon 3 (codon 59 & 61), and exon 4 
(codon 117 and 146) is now considered the standard of care.28, 29 Including extended RAS 
mutations, 55.9% of mCRC patients are predicted to have an alteration that would result in a 
lack of benefit from anti-EGFR agents.31 While the evidence to support KRAS exon 2 mutations 
as a predictive biomarker is quite firm, with a positive interaction test in a placebo controlled 
trial, the predictive nature of many of the less common variants remains unclear.10 For 
example, only 7 patients with codon 59 mutations were identified in the PRIME trial that 
demonstrated extended RAS variants had clinical relevance.28 These mutations were not part 
of the extended RAS mutation analysis, but rather were assessed in a post-hoc analysis that 
showed that removing them from the wild type population resulted in a smaller hazard ratio 
favoring FOLFOX + panitumumab.30 Case reports demonstrating activity of anti-EGFR agents 
for patients with RAS mutations are numerous and even among exon 2 mutations, there has 
been much exploration about whether all variants are equally relevant.32, 33 Prior retrospective 
studies suggested that patients with KRAS G13D mutations had improved OS and PFS 
following treatment with anti-EGFR agents compared to other KRAS mutations.34, 35 This 
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resulted in the prospective ICECREAM trial which attempted to validate the hypothesis that 
KRAS G13D mutated mCRC may still benefit from anti-EGFR treatment. Unfortunately, there 
were no responses in G13D mutated mCRC patients in the trial.36  
 
Beyond extended RAS mutations, other “atypical” variants in KRAS and NRAS have been 
noted and it remains unclear whether these variants are functionally activating or have clinical 
relevance.37 As sequencing capacity improves and we move beyond single gene and hot-spot 
annotation, these mutations are likely to become of increasing importance. Despite G13D being 
one of the most common RAS mutations, the ICECREAM study took over 2 years to recruit 53 
patients and demonstrated the difficulty in studying rare variants prospectively. If a similar 
prospective strategy is utilized to validate all of the rare atypical variants that are being 
discovered, it is unlikely that we will be successful in answering our question as to whether 
these variants have clinical relevance and alternative strategies are required. 
 
Beyond defining the individual mutations of relevance within RAS, understanding the impact of 
tumor heterogeneity and low frequency mutations in these genes raises further questions about 
defining the optimal population for treatment with anti-EGFR agents. While traditional PCR or 
Sanger sequencing identified mutations if >10% of cells had a mutation, newer techniques 
have sensitivities to detect variants in as few as 0.01% of cells.38, 39 These low frequency 
mutations may be responsible for treatment failure of anti-EGFR therapies in patients 
previously defined as wild type. In the CAPRI-GOIM trial, the use of a more sensitive next 
generation sequencing (NGS) assay than standard of care testing resulted in a further 15.9% of 
patients being identified as RAS mutant despite similar assay coverage.40 These patients had 
inferior outcomes to RAS wild type patients and appeared to have a similar prognosis to high 
allele frequency RAS mutant patients. These findings have been demonstrated by numerous 
other groups, however it remains unclear if there is an allele frequency threshold at which anti-
EGFR agents may still be active.41–43 In CRYSTAL, the use of high sensitivity BEAMing to 
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determine RAS status was able to evaluate allele frequencies down to 0.1%.44 This 
demonstrated that at low but detectable allele frequencies, the addition of anti-EGFR agents 
may still benefit patients (HR 0.57, 95% CI 0.33-1.01) and there was a gradual increase in the 
HR favoring FOLFIRI alone as the allele frequency of RAS variants increased. Taken together, 
it seems reasonable that both the specific KRAS/NRAS variant and the allele frequency of a 
mutation may have clinical impact, however these concepts remain relatively unexplored. 
 
Summary of Introduction and Specific Aims of Thesis 
Over the past two decades there have been considerable advances in the treatment of CRC, 
with the introduction of new cytotoxic and targeted agents. Molecularly targeted agents are an 
important step forward in oncology, however are heavily reliant on predictive biomarkers to 
select the right patient for the right drug. Mutations in RAS have been shown to predict a lack of 
benefit from anti-EGFR agents and are present in a large proportion of mCRC patients. 
However, there is significant heterogeneity in the clinical course of RAS mutant patients and 
many RAS wild type patients still fail to respond to anti-EGFR therapy. As sequencing 
technology has advanced, we are now becoming aware of novel variants that are either at 
locations that were previously not sequenced or at allele frequencies that were not detected. 
Further characterization of these mutations and a greater understanding of how tumor 
heterogeneity impacts outcomes is required and we are left with the most important scientific 
question remaining unanswered. How do we apply these findings to our patients? The specific 
aims of this thesis are: 
Aim 1: To describe the functional and clinical significance of atypical RAS mutations. 
Aim 2: To assess the impact of RAS mutant allele frequency on clinical outcomes in mCRC. 
Aim 3: To evaluate whether allele frequency of mutations can be used as a predictor of 
functional impact.  
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Chapter 2: Materials and Methods 
Description of Study Population and Development of Cohorts 
Two separate clinical cohorts were built to facilitate the analyses performed in this thesis at MD 
Anderson (MDA) with data extracted from a mixture of sources including the MDA tumor 
registry, the MDA Pathology Department, and from clinical chart review.  
1. MDA T200 Cohort – This cohort consists of 207 patients with mCRC who had a 201 
gene NGS panel performed on their tumor. These patients were seen at MDA between 
January 1, 2012 and September 1, 2016 and the database has an OS event rate of 
87.4%. Available variables include age, gender, date of diagnosis, stage at diagnosis, 
date of stage IV diagnosis, site of biopsy, date of death or last follow up, vital status, 
histology, MSI status, tumor location, tumor content in biopsy, and mutation status 
including single nucleotide variants (SNV), insertions/deletions (indels), allele frequency 
and copy number alterations. 
2. MDA CMS 46 Cohort – This cohort consists of 1877 patients with mCRC who had a 46 
gene NGS panel performed on their tumor. These patients were seen at MDA between 
January 1, 2012 and September 1, 2016 and the database has an OS event rate of 
58.7%. Available variables include age, gender, date of diagnosis, stage at diagnosis, 
date of stage IV diagnosis, site of biopsy, date of death or last follow up, vital status, 
histology, MSI status, tumor location, tumor content in biopsy and mutation status 
including single nucleotide variants and allele frequency. 
In addition to the 2 cohorts described above, 5 separate cohorts with NGS results but minimal 
clinical annotation were utilized to facilitate assessment of atypical RAS mutation prevalence. 
These cohorts included: 
1. cfDNA Cohort – This cohort consists of 1397 CRC patients who underwent cfDNA 
testing between June 1, 2014 and May 18, 2016 with a Guardant360TM NGS assay 
globally. Patients who had an assay without a variant detected were not included in the 
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analysis (272 patients excluded). The Guardant360TM assay has been previously 
described and was performed centrally by Guardant Health.45 The assay has a 
predicted sensitivity of 0.1% mutant allele frequency.  
2. Project Genie Cohort – Publicly available data from the AACR Project Genie was used 
and consists of 2081 patients with CRC who had an NGS panel performed at 1 of 8 
international centers. Each center that is part of Project Genie utilizes its own 
sequencing assay and bioinformatic pipeline, each of which are described in Project 
Genie’s data guide.46  
3. Caris Life Sciences Molecular Diagnostics Cohort – In collaboration with Caris Life 
Sciences, we have assessed their sequencing database for the prevalence of all RAS 
mutations detected using their NGS assay in CRC patients. No clinical annotation or 
mutational data outside of the KRAS/NRAS genes is available for this data set. 
4. The Cancer Genome Atlas (TCGA) CRC Cohort – Publicly available data from 228 
patients in the TCGA colorectal characterization was downloaded to assess atypical 
RAS mutation prevalence in this cohort which includes whole exome sequencing 
results.19 Clinical annotation was not downloaded. 
5. Nurses’ Health Study/ Health Professionals Study (NHS/HPFS) Colorectal Cohort – 
Publicly available data from 619 patients in the NHS/HPFS with colorectal cancer and 
whole exome sequencing was downloaded to assess atypical RAS mutation prevalence 
in this cohort which includes whole exome sequencing results.47 
Molecular Techniques 
Next Generation Sequencing for MDA CMS 46 Cohort 
Tumor sequencing was performed in the CLIA environment of MDA’s Molecular Diagnostics 
Laboratory. Archival formalin-fixed paraffin embedded (FFPE) samples from either surgical 
resection specimens or tissue biopsies with >20% tumor content were used for sequencing 
after macro-dissection. Sequencing results from primary tumors or metastatic tumor biopsies 
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were considered together as prior evidence suggests a high level of concordance between 
primary and metastatic lesions.29 DNA extraction used a PicoPure DNA extraction kit (Arcturus, 
Mountain View, CA) and was purified using an Agencourt AMPure XP kit (Agencourt 
Biosciences, Beverly, MA). DNA quantification was performed with a Qubit DNA assay kit 
(ThermoFisher Scientific, Waltham, MA). Library preparation was performed using the Ion 
Torrent AmpliSeq 2.0 Beta kit and Ion Torrent Ampliseq Cancer Panel Primers (Life 
Technologies, Grand Island, NY). Until September 10, 2013, version 1.0 of the panel which 
included 46 cancer related genes was utilized. Subsequently, version 2.0 of the panel was 
used which included an additional 4 genes. For patients who had version 2.0, only the 46 
genes used for the entire cohort were assessed. Sequencing was performed using an Ion 
Torrent Personal Genome Machine Sequencer and adequately covered amplicons were 
defined as those with a depth of ≥250X. Sequence alignment and base calling were performed 
using the Torrent Suite software version 2.01 and variant calling was performed with Torrent 
Variant Caller software version 1.0 with Human Genome Build 19 as the reference. Routine 
germ line testing was not performed. Tested codons and genes have been previously 
described48.  
Next Generation Sequencing for MDA T200 Cohort 
DNA extraction and purification was performed using the same techniques as the CMS46 
cohort, however matched germline DNA was also extracted and sequenced. The T200 panel is 
a capture based targeted exome panel that provides high depth coverage for all exons in 201 
cancer-related genes and provides information regarding mutations, indels, and copy number 
alterations. The panel has previously been described and contains 4874 exons encoding 
938,607 bases.49  DNA from each sample is sheared by sonication and prepared for library 
creation using the KAPA library prep kit (Woburn, MA). Targeted capture is performed with 
biotin labeled Roche Nimblegen DNA probes (Indianapolis, IN). The capture process occurred 
via the manufacturer’s protocol. Captured libraries were sequenced on an Ilumina HiSeq 2000 
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(San Diego, CA) on a version 3 TruSeq paired end flow cell. FASTQ files were demultiplexed 
using CASAVA 1.8.2 and regions required >20 reads to be considered adequately covered. 
Sequence alignment was performed with BWA using human reference genome hg19 and 
duplicated reads were removed using Picard.50, 51 VarScan2 was used to call single nucleotide 
variants (SNVs), and copy number was called using Lonigro et al’s previously published 
pipeline.52, 53 Sequencing results from tumor and germline were compared and germline 
variants were filtered from tumor sequencing results. 
Microsatellite Instability (MSI) Testing 
MSI status was retrospectively reviewed from patient’s charts for both MDA cohorts and was 
only evaluated in patients who had testing performed as part of their standard care. Testing 
consisted of a mixture of immunohistochemical (IHC) staining for mismatch repair protein 
deficiency (MLH1, MSH2, PM2, MSH6) and PCR based assessment of microsatellite status. 
For the PCR based assessment, a total of 7 markers (BAT25, BAT26, D2S123, D5S346, 
D17S250, TGFβRII, and BAT40) were tested in a multiplex PCR assay that incorporates 
fluorescently labeled primers to detect instability of nucleotide repeats in microsatellites. 
Tumors were defined as MSI-H if either method (IHC or PCR) of detection was abnormal. 
Relative Impact of Atypical RAS Mutations on Outcomes 
Prevalence of RAS Mutations 
In order to determine the prevalence of specific RAS variants and their corresponding 
categorization we utilized internal, external, and publicly available databases that included NGS 
results from patients with CRC. A total of 8609 patients were included in the analysis from 7 
cohorts [Table 1]. For patients with more than one mutation in KRAS or NRAS, variants were 
considered independently for calculating the specific mutations prevalence. However, these 
patients were categorized into typical (KRAS codon 12 & 13), extended (KRAS codon 59, 61, 
117, 146 or NRAS codon 12, 13, 59, 61, 117, 146), or atypical (all other KRAS/NRAS variants) 
with preference given in descending order from typical to extended to atypical mutations for all  
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Table 1. Cohorts utilized to characterize relative prevalence of RAS mutations in colorectal 
cancer and their characteristics. 
Cohort 
MDA 
CMS 4669 
MDA 
T20049 
CARIS 
Project 
Genie46 
TCGA19 
NHS & 
HPFS47 
Guardant 
36045 
Number of 
Patients 
1877 207 2200 2081 228 619 1397 
RAS 
Coverage 
Hot spot 
All 
exons 
All 
exons 
Mixed 
All 
exons 
All 
exons 
All exons 
Assay 
Type 
Multiplex 
Capture 
Based 
Multiplex Mixed Exome Exome cfDNA 
Assay 
Depth 
≥250X 
Median 
906X 
(tumor) 
>750X 
Varied 
by 
Platform 
>20X for 
80% of 
exons 
Median 
88X 
(tumor) 
8000X 
Tumor 
Cellularity 
>20% >20% >20% >10% ≥60% 
Average 
45% 
n/a 
Stage of 
Patients 
Stage IV Stage IV Stage IV 
Mostly 
Stage IV 
Stage 
I-IV 
Stage 
I-IV 
Mostly 
Stage IV 
Publicly 
Available 
No No No Yes Yes Yes No 
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further analysis. RAS mutations were categorized into typical, extended and atypical variants 
based on prior literature.29  
Functional Characterization of RAS Mutations 
NovellusDx Functional Annotation for Cancer Treatment (FACT) Assay 
Functional significance was assessed for all RAS variants (a) detected at MDA among patients 
who received a CMS 46 NGS assay for any malignancy, (b) present in a CRC patient in the 
CARIS Life Sciences Molecular Diagnostics database, or (C) noted to be of clinical significance 
or with prior functional annotation in PubMed or COSMIC.62 For example, KRAS P34R has 
been associated with cardiofaciocutaneous syndrome (CFC) and KRAS T58I is associated with 
Noonan syndrome. As these have both been well characterized to increase cellular 
proliferation, decrease KRAS GTPase activity, and stimulate down-stream phosphorylation of 
MEK, they served as a reasonable control for activating atypical alterations.63, 64  
 
Characterization occurred using the NovellusDx FACT Assay in a CLIA-certified laboratory. 
Mutations were generated over a wild-type transfection vector and co-transfected into a HeLa 
cell line based assay with a GFP-ERK reporter construct. Upon phosphorylation and activation, 
ERK moves from the cytoplasm to the nucleus. Using this assay, MAPK pathway activation 
was characterized as the relative localization of GFP-ERK to the nucleus using fluorescent 
microscopy for detection. Each mutation was then normalized to a wild-type transfection by 
establishing the assay output of wild type transfection as a value of 1.0, and converting all other 
measurements to fold change from wild-type. Within each run of the assay, thousands of cells 
undergo transfection within each well as biologic repeats and each mutation had 8 technical 
repeats of the assay performed. Changes from wild-type transfection were compared using 
Student’s t-test and a value of P<0.05 was deemed significant. Correction for multiple testing 
was not performed. Graphical presentation represents mean +/- standard deviation. 
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In the analysis comparing OS based on functional activity as defined by the NovellusDx assay, 
a cut point of the median functional activity of all variants characterized (1.46) was utilized 
rather than a patient weighted median (1.35), as the patient weighted median would have split 
the KRAS exon 2 mutations evenly between “high” and “low” activity groups, and these variants 
are known to be predictive biomarkers for resistance to anti-EGFR agents. BRAF V600 
mutated patients were excluded from all survival analysis to ensure differences between 
groups were not dependent on other MAPK alterations. 
Ba/F3 Transformation Assay 
In order to validate the findings of the NovellusDx FACT assay, we utilized the Ba/F3 
Transformation Assay. A selection of 13 RAS mutations representing typical, extended, 
atypical, activating, and non-activating (per the NovellusDx assay) mutations were assessed 
using the well described Ba/F3 transformation assay in collaboration with Dr. Gordon Mills and 
Dr. Patrick Kwok-Shing Ng.65, 66 Ba/F3 cells were cultured using RPMI medium with 5% FBS 
and 1 ng/mL of IL-3. The 13 mutations and a wild type construct were cloned into pHAGE 
vector by HiTMMoB technique.67 Lentivirus was generated in LentiX-293T cells by transfecting 
the pHAGE and two packaging plasmids (psPAX2 and pMD2.G). The virus was harvested 3 
days after transfection by filtering with 0.45 µM filter paper. Ba/F3 cells (0.6 million cells) were 
transduced with 900 µL of virus containing medium by spinoculation at 1000X gravity for 3 
hours in the presence of polybrene (8µg/mL). After spinoculation, cells were suspended in 
medium without IL-3. Transduced cells were incubated at 37ºC for 3 days and cell viability was 
measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). 
Cell viability was compared to wild type using Student’s t-test. Ba/F3 cells are normally 
dependent on IL-3 for survival and require its addition to media. After successful transfection of 
a functionally active oncogene these cells are able to survive the withdrawal of IL-3, while 
mutations that are not transforming will result in cells death. Wild type cell viability was 
assessed with 4 technical repeats and each mutation was assessed with 2 technical repeats. 
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Comparison of RAS Mutations Based on Allele Frequency 
RAS mutation allele frequency was assessed for clinical significance in patients from the MDA 
T200 cohort and the MDA CMS 46 cohort. In order to normalize the allele frequency of 
mutations to tumor content, we performed a calculation that directly compared RAS mutant 
allele frequency to the allele frequency of whichever mutation was detected in that patient at 
the highest allele frequency. This high allele frequency mutation was considered the most 
“truncal” mutation and chosen to represent tumor content.  
 
rMAFRAS = 
𝑹𝑨𝑺 𝑴𝒖𝒕𝒂𝒕𝒊𝒐𝒏 𝑨𝒍𝒍𝒆𝒍𝒆 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚
𝑻𝒓𝒖𝒏𝒄𝒂𝒍 𝑴𝒖𝒕𝒂𝒕𝒊𝒐𝒏 𝑨𝒍𝒍𝒆𝒍𝒆 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚
 
Sensitivity analyses were performed using the pathologist assessed tumor content in place of 
the truncal mutation. For patients with a T200 panel, copy number information was available. 
Correction for copy number alterations was applied to take into account amplifications of RAS 
or copy number losses in key truncal tumor suppressors such as TP53. The modified formula 
was as follows: 
rMAFRAS corrected for CNA= 
𝑹𝑨𝑺 𝑴𝒖𝒕𝒂𝒕𝒊𝒐𝒏 𝑨𝒍𝒍𝒆𝒍𝒆 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚∗( 
𝟐
𝑹𝑨𝑺 𝑪𝒐𝒑𝒚 𝑵𝒖𝒎𝒃𝒆𝒓
 )
𝑻𝒓𝒖𝒏𝒄𝒂𝒍 𝑴𝒖𝒕𝒂𝒕𝒊𝒐𝒏 𝑨𝒍𝒍𝒆𝒍𝒆 𝑭𝒓𝒆𝒒𝒖𝒆𝒏𝒄𝒚∗( 
𝟐
𝑻𝒓𝒖𝒏𝒄𝒂𝒍 𝑪𝒐𝒑𝒚 𝑵𝒖𝒎𝒃𝒆𝒓
 )
 
For all comparisons between groups that utilized rMAF RAS to stratify patients, we excluded 
BRAF V600 mutant patients. A cut point to dichotomize patients into high and low allele RAS 
mutant groups was chosen at an rMAF of 50% with the biologic rationale that this would be 
comparing patients with greater than half of their tumor comprised of RAS mutant clones to 
those with less than half. The median was not chosen as it was a RAS rMAF of >75%, which 
from a biologic perspective was not deemed a reasonable cut point. This would have resulted 
in many of the patients in the “low” allele frequency group having a nearly clonal mutation. 
Given the debate regarding the discrepancy between pathologist estimates of tumor content 
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and true tumor content, we a-priori planned to primarily use the molecularly defined rMAF for all 
analyses.54  
Relative Mutant Allele Frequency as a Predictor of Functional Significance  
In addition to assessing the impact of RAS rMAF, we aimed to determine whether rMAF of a 
variant could be used as a predictor of a mutations functional significance. This work utilized 
the MDA T200, MDA CMS46, cfDNA, and Project Genie cohorts described in the methods. All 
variants detected within each of the cohorts had their functional significance categorized as 
described below. 
Assignment of Functional Significance to NGS Variants in Aim 3 
Functional significance of variants was performed by cross referencing individual variants with 
4 separate measures of functional significance. These methods included:  
1. “PODS” Functional Annotation - The Precision Oncology Decision Support Core at MDA 
has a large database of functionally annotated variants that categorizes variants as 
activating, inactivating, likely benign, or unknown based on a review of all available 
literature as well as in-vitro assessment of functional significance for many variants and 
has been previously described.55  
2. SIFT scores – A SIFT score predicts whether the amino acid substitution that results 
from a mutation will be functionally relevant and is computationally defined.56 A score of 
0-0.05 is considered “deleterious” and a score of 0.05 to 1.0 is considered “tolerated.” 
SIFT scores were assigned to the MDA T200 cohort and Project Genie cohort during 
their primary bioinformatic work and these values were used for analysis. For the MDA 
CMS 46 and cfDNA cohorts, all variants were cross referenced to assigned SIFT scores 
in the Project Genie cohort to ensure uniformity. 
3. Polymorphism Phenotyping (Polyphen) scores - A Polyphen score predicts whether the 
amino acid substitution that results from a mutation will be functionally relevant and is 
computationally defined.57 Polyphen assigns a score between 0.0 (benign) to 1.0 
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(damaging) and patients are grouped into benign, possibly damaging, and probably 
damaging based on its score and a qualitative assessment of the algorithm. Polyphen 
scores were assigned to the Project Genie cohort during its bioinformatic pipeline. The 
MDA CMS 46, MDA T200 and cfDNA cohorts had all variants cross referenced to 
assigned Polyphen scores in the Project Genie cohort to insure uniformity.  
4. SIFT/Polyphen Merged Predicted Functional Significance – This measure was 
composed of a score between 0 and 4, with points assigned based on the SIFT and 
Polyphen scores considered together for each variant. In SIFT, a point was given for 
variants deemed to be possibly deleterious (low confidence) and 2 points were given for 
deleterious variants. In Polyphen, 1 point was given for possible damaging and 2 points 
for probably damaging. Variants were only considered if at least 1 of the scores made a 
functional prediction for that mutation.   
In addition to studying predictive scores for defining the functional significance of a variant, we 
also performed two case-studies to evaluate whether a model of increasing rMAF was 
compatible with a determination of functional significance. The first case-study reviewed rMAF 
of BRAF V600 and non-V600 mutations across all 4 previously described cohorts. There has 
been growing evidence that BRAF V600 mutations are responsible for the negative prognostic 
significance of BRAF mutations and that non-V600 mutations have less impact. 58, 59 As such, 
we predicted that BRAF V600 mutations would occur at higher rMAFs.  
 
Using the cfDNA cohort, we also aimed to determine whether there was a correlation between 
the number of mechanisms of resistance detected within a patient to anti-EGFR therapy to the 
rMAF of those mechanisms of resistance. From an evolutionary perspective, the development 
of resistance often comes at a cost for a microorganism or tumor cell. These costs can be 
either a reduced fitness or the uncovering of a collateral sensitivity.60, 61 Based on this theory, if 
a malignant cell has developed a mechanism of resistance to a targeted agent, there would be 
little benefit to developing multiple other mechanisms within the same cell. There may however 
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be other clonal populations that exist within the patient that develop alternate mechanisms of 
resistance. cfDNA allows the sampling of all clones secreting DNA into a patient’s blood stream 
and provides a contemporary view of the genomic landscape within a patient at the time that 
blood is drawn. We predicted that patients with a single mechanism of resistance detected may 
have this mutation at a high allele frequency. In patients with multiple concurrent alterations, 
the average rMAF of those alterations should be lower, as these patients likely have a more 
diverse clonal structure and we would expect that each of those mechanisms would only be 
present in a portion of the total tumor cell population. There was no clinical annotation available 
for this cohort to confirm prior receipt of an anti-EGFR agent in patients. Mechanisms of 
resistance included alterations to EGFR, KRAS, NRAS, BRAF, MAP2K1, ERBB2, MET, and 
KIT. A mechanism of resistance could include either an amplification or a single nucleotide 
variant, however only single nucleotide variants were assessed for average rMAF. 
Statistical Analysis 
Categorical characteristics were compared using the χ2 test or Fisher’s exact test as 
appropriate, while continuous variables were compared with the Mann-Whitney or Kruskal-
Wallis tests when a median is reported and the Student’s t-test or ANOVA when averages are 
shown. Correction for multiple testing was not performed. P<0.05 is considered significant for 
all analyses. Right sided tumors were defined based on pathology and surgical reports as 
those occurring from the cecum up to but not including the splenic flexure. Left sided tumors 
were defined as those occurring from the splenic flexure to the rectum. OS was defined as the 
time from diagnosis with stage IV CRC until death or last follow up. Patients alive at the time of 
last follow up were censored. OS was summarized using Kaplan-Meier curves and compared 
using the log-rank test and Cox-regression analysis. Where multivariate models were 
performed, a forward likelihood ratio selection was used. Variables with p<0.1 were included. 
All variables met the proportional hazards assumption and were chosen based on differences 
in baseline characteristics between groups or known prognostic features in CRC.  
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Analysis was performed using Graph Pad Prism software version 5.0 (La Jolla, California), 
SPSS version 22.0 (Armonk, New York) and R studio version 3.30 (Boston, MA). Data 
visualization also utilized the R package ggplot2.68 
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Chapter 3: Results 
Aim 1: To describe the functional and clinical significance of atypical RAS 
mutations. 
Prevalence of Atypical RAS Mutations 
The prevalence of missense, nonsense, and indel mutations in RAS was assessed across 7 
cohorts [Figure 3 & 4]. Mutations in RAS were noted in 4244/8609 patients (49.3%), and varied 
significantly between cohorts (P<0.0001) with a range in prevalence from 32.1% to 53.3%. 
Data from the Project Genie collaboration includes patients with a variety of NGS platforms. 
Given the heterogeneity in techniques used, data is presented for the entire available cohort 
(N=2081) and for only those patients who utilized assays that would cover all exons of 
KRAS/NRAS (depicted with a *). There was no statistically significant difference in RAS 
mutation frequency (P=0.31) or distribution of RAS mutation category (ie. typical, extended, 
atypical, P=0.65) noted between the two versions of the cohort.  
 
A total of 3314/4244 (78.1%) RAS mutant patients had typical mutations, 822/4244 (19.4%) 
had extended RAS mutations and 108/4244 (2.5%) had atypical RAS mutations.29 One 
hundred and twenty three atypical variants were detected, with 84 occurring in KRAS and 39 in 
NRAS. Fifteen of these variants occurred in patients who had a co-occurring typical or 
extended mutation and they were categorized according to their more common variant. 
Prevalence of individual variants are summarized in Table 2, and although most atypical 
variants occur at very low frequencies, certain variants are present in a larger proportion of 
patients than guideline cited variants. For example, KRAS Q22K was noted in 13/8609 (0.2%) 
patients, and yet not a single NRAS codon 117 or 146 variant was detected in the entire cohort 
and only 1 NRAS codon 59 variant was detected. Other atypical variants occurring at 
frequencies of ≥0.1% include KRAS L19F (7/8609, 0.1%), KRAS D33E (7/8609, 0.1%), and 
KRAS T50I (5/8609, 0.1%).   
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Figure 3.  Prevalence of RAS mutations based on category of mutation in colorectal cancer 
across 7 cohorts. Project Genie* = Project Genie cohort restricted to only the 1149 patients with 
all exons of KRAS/NRAS sequenced. 
 
Figure 4.  Proportion of RAS mutations that are defined as typical, extended, or atypical in 
colorectal cancer across 7 cohorts. Project Genie* = Project Genie cohort restricted to only the 
1149 patients with all exons of KRAS/NRAS sequenced. 
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Table 2. Prevalence of specific RAS mutations detected across 7 cohorts. 
Gene Alteration N 
Prevalence 
(%) 
Gene Alteration N 
Prevalence 
(%) 
KRAS L6P 1 0.0% NRAS A11S 1 0.0% 
 V7E 1 0.0%  A11T 1 0.0% 
 V9_G10dup 1 0.0%  G12A 6 0.1% 
 G10dup 1 0.0%  G12C 17 0.2% 
 A11_G12dup 1 0.0%  G12D 55 0.6% 
 G12A 172 2.0%  G12R 2 0.0% 
 G12C 268 3.1%  G12S 7 0.1% 
 G12D 1164 13.5%  G12V 11 0.1% 
 G12E 1 0.0%  G13C 2 0.0% 
 G12F 5 0.1%  G13D 13 0.2% 
 G12L 1 0.0%  G13R 15 0.2% 
 G12R 51 0.6%  G13V 4 0.0% 
 G12S 166 1.9%  Q22K 1 0.0% 
 G12V 769 8.9%  Q25* 1 0.0% 
 GC12-13ES 1 0.0%  Q25H 1 0.0% 
 G13C 16 0.2%  V29L 1 0.0% 
 G13D 693 8.0%  E31K 1 0.0% 
 G13dup 1 0.0%  E49* 1 0.0% 
 G13H 1 0.0%  L53F 1 0.0% 
 G13R 6 0.1%  D54V 1 0.0% 
 G13V 2 0.0%  D57Y 2 0.0% 
 V14I 4 0.0%  A59T 1 0.0% 
 G15S 1 0.0%  G60E 1 0.0% 
 A18D 1 0.0%  G60R 1 0.0% 
 L19F 7 0.1%  Q61H 20 0.2% 
 T20M 1 0.0%  Q61K 104 1.2% 
 I21T 1 0.0%  Q61L 43 0.5% 
 Q22K 13 0.2%  Q61R 53 0.6% 
 E31E 1 0.0%  E62K 1 0.0% 
 E31K 1 0.0%  E62L 1 0.0% 
 D33E 7 0.1%  A66T 1 0.0% 
 S39Pfs*6 1 0.0%  E98V 1 0.0% 
 E49X 1 0.0%  D105Tfs*9 1 0.0% 
 T50I 5 0.1%  S106L 1 0.0% 
 L56V 1 0.0%  D108G 1 0.0% 
 D57N 1 0.0%  V114A 1 0.0% 
 A59E 3 0.0%  T122R 1 0.0% 
 A59G 7 0.1%  D126V 1 0.0% 
 A59T 14 0.2%  Q129H 1 0.0% 
 G60D 1 0.0%  E132K 3 0.0% 
 G60V 1 0.0%  K147R 1 0.0% 
 Q61K 20 0.2%  E162* 1 0.0% 
 Q61L 40 0.5%  R164C 2 0.0% 
24 
 
Gene Alteration N 
Prevalence 
(%) 
Gene Alteration N 
Prevalence 
(%) 
KRAS Q61H 131 1.5% NRAS G138R 1 0.0% 
 Q61P 1 0.0%  R167Q 1 0.0% 
 Q61R 17 0.2%  M168I 1 0.0% 
 E62K 1 0.0%  K170N 1 0.0% 
 A66_M67ins* 1 0.0%  P185A 1 0.0% 
 R68S 4 0.0%  V188M 1 0.0% 
 Y71D 1 0.0%  c.451-
11dupT 
1 0.0% 
 M72L 1 0.0%  Wild Type 8217 95.4% 
 E76G 1 0.0%  Total 8609 100.0% 
 E98* 1 0.0%     
 E98X 1 0.0%     
 V109A 1 0.0%     
 N116H 1 0.0%     
 K117N 30 0.3%     
 K117R 1 0.0%     
 Q131H 1 0.0%     
 T144I 1 0.0%     
 A146P 11 0.1%     
 A146T 173 2.0%     
 A146V 49 0.6%     
 K147E 1 0.0%     
 K147N 2 0.0%     
 K147T 1 0.0%     
 F156V 1 0.0%     
 L159Wfs*2 1 0.0%     
 R164* 1 0.0%     
 R164Q 1 0.0%     
 E168fs 1 0.0%     
 K170Q 1 0.0%     
 K176N 1 0.0%     
 K177del 1 0.0%     
 K178del 1 0.0%     
 P178L 1 0.0%     
 K185fs 1 0.0%     
 c.291-10delT 1 0.0%     
 Wild Type 4708 54.7%     
 Total 8609 100.0%     
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Functional Impact of Specific RAS Mutations 
Using the NovellusDx FACT assay we transfected 113 different RAS mutations (61 KRAS and 
52 NRAS) in a live cell reporter assay. Mutations that resulted in nuclear localization of GFP-
ERK that was significantly greater than wild type transfection are considered “activating,” while 
those that did not significantly increase nuclear localization of GFP-ERK were deemed “non-
activating” [Figure 5 & 6]. Values represent the average of 8 repeats for each mutation and 
have been normalized to the wild type transfection of KRAS or NRAS (mutation dependent) to 
represent a fold change from wild type transfection. Of 61 KRAS mutations characterized, 6 
were not activating and included I21L, E49*, D57N, E76G, E98* and K176N. Of 52 NRAS 
mutations characterized, 17 were not activating and included G10E, A11T, A18T, I21V, V29L, 
E31K, D54V, D57Y, A66T, M67I, D126V, E132K, K135N, G138R, R164C, R167Q and P185A.  
 
All non-activating RAS variants were atypical mutations and all typical or extended mutations 
were shown to be activating. Relative MAPK activity summarized by atypical/typical/extended 
categorization is summarized in Figure 7 and demonstrates that extended mutations resulted in 
the highest MAPK activity, which was greater than both typical (P=0.0018) or atypical 
(P<0.0001) mutations. After weighting each variant based on their prevalence in the MDA CMS 
46 cohort of 1877 mCRC patients [Figure 7- C], we noted that the recurrent atypical variants 
present in patients were those of higher activity, rather than the non-activating mutations. In 
fact, all atypical variants in this cohort were those that resulted in a functional activity in the top 
10%ile of all patients. 
 
More atypical mutations were shown to be non-activating for NRAS (17/26 tested atypical 
mutations) than for KRAS (6/31 tested atypical mutations) (P=0.0004). In addition, though the 
median MAPK activity of all assessed KRAS (Median 1.46, IQR 1.27-1.60) and NRAS (Median 
1.53, IQR 1.15-1.90) mutations did not differ (P=0.52), when we weighed the 
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Figure 5. Functional impact of KRAS variants on MAPK signaling and nuclear GFP-ERK localization following transfection in the Novellus 
Dx FACT assay. Values have been normalized to a wild type transfection and represent fold change from wild type. Each mutation was 
assessed with 8 technical repeats. Values represent mean +/- standard deviation. 
27 
 
 
Figure 6. Functional impact of NRAS variants on MAPK signaling and nuclear GFP-ERK localization following transfection in the Novellus 
Dx FACT assay. Values have been normalized to a wild type transfection and represent fold change from wild type. Each mutation was 
assessed with 8 technical repeats. Values represent mean +/- standard deviation.
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Figure 7. Functional impact of all KRAS and NRAS mutations on MAPK pathway signaling 
categorized by mutation category. (A) Values represent Kernel Density plot of probability at 
each functional activity fold change compared to wild type which was considered an activity of 
1.0. (B) Median activity of each assessed variant and (C) weighted median activity based on 
prevalence of each assessed mutation. 
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activity scores by the prevalence of each variant in our MDA CMS 46 cohort, patients with 
NRAS mutations (Median 1.93, IQR 1.45-2.09) had mutations resulting in higher activity than 
patients with KRAS mutations (Median 1.35, IQR 1.35-1.38) (P<0.0001) [Figure 8 - C].  Of all 
23 mutations that did not increase MAPK signaling, only KRAS E98*, NRAS D57Y, NRAS 
E132K, and NRAS R164C were recurrently identified in >1 CRC in our pooled cohort of 8609 
mCRC patients. As well, KRAS I21L, NRAS G10E, NRAS A18T, NRAS I21V, NRAS M67I and 
NRAS K135N have only been identified in non-CRC malignancies. In total, only 22/8609 
patients (0.3%) had a RAS mutation that was non-activating in the pooled cohort.  
 
In the hopes of identifying patients with mutations that may have signaling activity close to wild 
type, we reviewed the specific variants that occurred at the lowest functional activities. No 
atypical variants fell in this category. Variants detected commonly in the MDA CMS 46 cohort in 
the bottom 10% of signaling activity included KRAS G13C (3/1877), KRAS G13R (2/1877), 
KRAS Q61L (12/1877), KRAS A146P (4/1877), KRAS G12S (34/1877). Any variants with 
signaling higher than these mutations were well characterized activating KRAS exon 2 
mutations. 
 
In addition to the NovellusDx FACT assay, a select number of RAS mutations representing 
typical, extended, atypical, activating, and non-activating mutations were assessed using the 
well described Ba/F3 transformation assay in collaboration with Dr. Gordon Mills and Dr. 
Patrick Kwok-Shing Ng.65, 66 All 13 mutations assessed using the Ba/F3 assay were concordant 
in their categorization of mutations as activating/non-activating with the NovellusDx FACT 
assay [Figure 9]. This included 2 non-activating atypical mutations (KRAS D57N and NRAS 
K135N) that were concordant between the two assays and a third atypical mutation (KRAS 
R68S) that was activating in both assays. 
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Figure 8. Functional impact of all KRAS and NRAS mutations on MAPK pathway signaling 
categorized by gene. (A) Values represent Kernel Density plot of probability at each functional 
activity fold change compared to wild type which was considered an activity of 1.0. (B) Median 
activity of each assessed variant and (C) weighted median activity based on prevalence of 
each assessed mutation. 
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Figure 9. Functional impact of KRAS/NRAS mutations introduced into the Ba/F3 cell 
transformation assay. Values represent mean +/- standard deviation. 
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Impact of RAS Mutation Category and Functionality on Clinical Outcomes  
Baseline characteristics stratified by RAS mutation category and functional annotation for the 
MDA CMS 46 cohort are shown in Table 3 and 4. Atypical mutations were numerically less 
common with mucinous or signet ring histology (P=0.065) and were more commonly 
associated with BRAF V600 mutations (P<0.0001). RAS mutations with activity above the 
median fold change for all characterized mutations were numerically less common with 
mucinous or signet ring histology (P=0.070). None of the atypical mutant patients from MDA 
with mCRC ever received an anti-EGFR agent.  
 
Prognostic impact of variants was assessed in only the MDA CMS 46 cohort. Patients with 
typical (HR 1.43, 95% CI 1.26-1.65, P<0.0001), extended (HR 1.61, 95% CI 1.39-2.20, 
P<0.0001), and atypical (HR 3.45, 95% CI 3.15-40.83, P=0.0002) RAS mutations had a worse 
OS than RAS/BRAF wild type mCRC patients [Figure 10]. There were no statistically significant 
differences between extended and typical RAS mutations (P=0.20), however atypical RAS 
mutations were associated with a worse OS than typical (HR 2.45, 95% CI 1.43-12.5, 
P=0.0092) but not extended (HR 1.97, 95% CI 0.99-6.92, P=0.055) RAS mutations.  In 
multivariate models controlling for primary tumor location, synchronous metastases at 
diagnosis, histology, age, gender and MSI, typical (P<0.0001) and extended (P=0.0010) 
mutations remained significantly associated with a worse OS, while atypical variants showed 
strong trends to worse OS (HR 2.62, 95% CI 0.97-7.06, P=0.055).  
 
Similar results were seen when considering KRAS mutations alone by category, where typical 
(HR 1.43, 95% CI 1.26-1.65, P<0.0001), extended (HR 1.53, 95% CI 1.24-2.20, P=0.0012), 
and atypical (HR 3.26, 95% CI 2.49-35.77, P=0.0064) KRAS mutations were associated with a 
worse OS. Among NRAS mutated patients, only 1 atypical variant was noted. Extended NRAS  
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Table 3. Baseline characteristics of metastatic colorectal cancer patients with RAS mutations according to category of mutation. 
 
Table 4. Baseline characteristics of metastatic colorectal cancer patients with RAS mutations according to activity of mutation. 
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Figure 10. (A) Overall survival of patients with metastatic colorectal cancer stratified by category of RAS mutation, (B) KRAS mutation 
category and (C) NRAS mutation category. Panel (D) demonstrates the prognostic relevance of KRAS/NRAS without categorization. 
Patients with BRAF V600 mutations were excluded from analysis. 
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mutations were associated with a worse overall survival (HR 1.74, 95% CI 1.43-2.88, 
P<0.0001) compared to wild type patients. When comparing all mutation categories together, 
NRAS mutations were associated with a worse OS than KRAS mutations (HR 1.34, 95% CI 
1.02-1.89, P=0.036). This appeared independent of the particular exon mutated in NRAS 
[Figure 11].  
 
Due to the wide dynamic range of activity noted in the NovellusDx FACT assay, we also 
compared RAS variants based on their functional activity. Of the 113 characterized mutations, 
the median functional activity was 1.46. Patients with RAS variants either below (HR 1.43, 95% 
CI 1.27-1.65, P<0.0001) or above (HR 1.66, 95% CI 1.42-2.37, P<0.0001) the median had a 
worse OS than patients with RAS/BRAF V600 wild type tumors [Figure 12 - A] but did not differ 
from each other in univariate (HR 1.16, 95% CI 0.94-1.46, P=0.17) or multivariate models 
(P>0.1).  
 
Because KRAS exon 2 mutations have been well characterized as a predictive biomarker, we 
next compared variants that were statistically higher or lower than the pooled average of KRAS 
exon 2 mutations. No patient had a variant that was significantly lower than KRAS exon 2, 
however 66 patients had variants that resulted in significantly higher signaling. These high 
signaling patients had variants that included KRAS V14I, KRAS Q22K, KRAS D33E, KRAS 
A146V, NRAS G12V, NRAS G13R, KRAS A59T and NRAS Q61R/L/K/H. Having one of these 
high signaling variants resulted in a worse OS (HR 1.40, 95% CI 1.04-2.08, P=0.028) than 
having a KRAS exon 2 mutation [Figure 12 - B]. In a multivariate model controlling for co-
variates, mutations with signaling activity significantly higher than exon 2 mutations (HR 1.81, 
95% CI 1.28-2.57, P=0.0010) were associated with a larger prognostic difference from RAS 
wild type patients than exon 2 mutations (HR 1.37, 95% CI 1.17-1.61, P<0.0001), however they 
were not significantly different when directly compared to each other [Table 5]. If a patient’s 
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MAPK activity change was considered as a continuous variable in Cox-regression models, it 
was associated with worse OS (HR 1.94, 95% CI 1.46-2.59, P<0.0001) [Table 3.5 – Model 3]. 
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Figure 11. (A) Overall survival of patients with metastatic colorectal cancer stratified by exon of 
KRAS or NRAS mutations showing no significant difference between (B) KRAS and NRAS 
exon 2 mutations or (C) KRAS and NRAS non-exon 2 mutations. Patients with BRAFV600 
mutations were excluded from analysis. 
 
 
 
  
38 
 
 
 
 
 
Figure 12. Overall survival of patients with metastatic colorectal cancer stratified by functional 
activation of a patients RAS variant stratified at the (A) median activity of 113 classified 
mutations and (B) by comparing patients with KRAS exon 2 mutations to any patients with a 
mutation resulting in MAPK activity significantly higher than KRAS exon 2.
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Table 5. Multivariate models comparing the impact of RAS mutation category and functional 
characterization on overall survival in metastatic colorectal cancer. Model 1 considers RAS 
mutations based on their category, model 2 considers RAS mutations based on their functional 
activity compared to KRAS exon 2 mutations, and model 3 considers the activity of RAS 
mutations as a continuous variable.
 
  
40 
 
Aim 2: To assess the impact of RAS mutant allele frequency on clinical 
outcomes in mCRC. 
Aim 2 utilized the MDA T200 cohort as a discovery cohort to evaluate cut points and perform 
sensitivity analyses, while the MDA CMS 46 cohort served as the validation cohort for 
prognostic differences between groups. 
Relative Mutant Allele Frequency as a Prognostic Marker in MDA T200 Cohort 
Of 207 sequenced mCRC cases, low allele frequency RAS mutations (rMAF <50%) occurred in 
21 patients (10.1%) and high allele frequency RAS mutations (rMAF >50%) occurred in 89 
patients (43.0%). The median RAS rMAF was 76.1%. After correcting for copy number 
alterations, 29 patients (14.0%) had low allele frequency RAS mutations and 81 patients 
(39.1%) had high allele frequency mutations. Median copy number corrected RAS rMAF was 
76.8%. Distribution of uncorrected and corrected rMAF is presented in Figure 13 and Figure 14 
and demonstrates the relative change in rMAF with correction for copy number alterations. 
Specific alterations used as the denominator in calculating rMAF are shown in Figure 14 - B. 
Patients were dichotomized into two groups at a 50% rMAF cut point for all further analysis. 
 
As seen in Table 6, there were no significant differences in baseline characteristics or 
mutational status based on allele frequency except low frequency variants were less common 
among patients with synchronous metastatic disease at diagnosis (38.1% vs 65.2%, P=0.023). 
Despite this, there was no difference in the distribution of site of biopsy (primary tumor vs 
metastases) between the two groups (P=0.65). Both RAS mutant groups were more likely to 
have right sided tumors (P=0.0062) or PIK3CA mutations (P=0.0022) than wild type patients 
and there were no BRAF V600 mutations among the RAS mutant groups but 8 among wild 
type patients (P=0.0062). Average sequencing coverage was lower in patients with RAS 
mutations at rMAF <50% compared to those with mutations at rMAF >50% (Average depth  
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Figure 13. Histogram of (A) RAS mutation relative mutant allele frequency (rMAF) and (B) RAS 
mutation rMAF corrected for copy number alterations among patients with metastatic colorectal 
cancer who received NGS with a T200 panel or (C) a CMS 46 panel.  
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Figure 14. (A) Impact of copy number alterations on the relative mutant allele frequency (rMAF) 
of RAS mutations and (B) mutations selected as the most truncal mutation for calculation of 
rMAF. 
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Table 6. Baseline characteristics of patients with metastatic colorectal cancer who underwent 
sequencing with a T200 panel stratified by RAS mutation relative mutant allele frequency 
(rMAF). 
 
*One patient with rMAF <50% and one RAS wild type patient had missing information regarding 
the site of biopsy. 
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485X vs 671X, P=0.027) and there were trends towards lower RAS coverage among the low 
allele frequency group (Average coverage 630X vs 852X, P=0.076).  
 
When comparing OS based on rMAF, patients with RAS rMAF >50% showed strong trends 
towards an association with worse OS than patients with RAS rMAF <50% (HR 1.59, 95% CI 
0.97-2.40, P=0.075) [Figure 15 - A]. Median OS was estimated at 55.4 months, 32.2 months, 
and 52.7 months for patients with RAS rMAF <50%, >50%, and wild type patients respectively. 
In multivariate models that controlled for age, MSI status, stage at diagnosis, age, histology, 
and primary tumor location, having a RAS mutation with an rMAF >50% was associated with a 
worse OS than wild type patients (HR 1.72, 95% CI 1.23-2.40, P=0.0010), while RAS mutant 
patients with rMAF <50% did not have a worse prognosis (HR 1.08, 95% CI 0.61-1.90, 
P=0.79). Other variables significant in the model included having stage IV disease at diagnosis 
and having a right sided primary [Table 7]. When high and low rMAF mutations were directly 
compared, they did not significantly differ. 
 
After correcting rMAF for copy number alterations, similar trends suggesting that higher allele 
frequency may be associated with a worse outcome were noted (HR 1.41, 95% CI 0.91-2.12, 
P=0.13), but again were not significant [Figure 15 – B]. In multivariate models using the copy 
number corrected rMAF, patients with rMAF >50% had a worse prognosis than wild type 
patients (HR 1.87, 95% CI 1.34-2.61, P<0.0001) but low allele frequency RAS mutations did 
not differ from wild type patients (HR 1.36, 95% CI 0.85-2.17, P=0.21). Of the other variables 
tested for inclusion in the multivariate model, only the presence of stage IV disease at 
diagnosis met criteria to remain in the model (HR 1.43, 95% CI 1.03-1.98, P=0.033) [Table 7]. 
When high and low rMAF mutations were directly compared, they did not significantly differ.  
 
As RAS mutations were occasionally truncal and may be impacted by amplifications, we 
performed a sensitivity analysis to ensure that patients with RAS mutations occurring in the  
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Figure 15. Impact of RAS mutation relative mutant allele frequency (rMAF) on overall survival in 
metastatic colorectal cancer. rMAF was calculated (A) as a direct comparison between RAS 
and the mutation with the highest allele frequency for a patient and (B) with consideration of 
copy number alterations. 
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Table 7. Multivariate models assessing the impact of RAS mutation relative mutant allele 
frequency (rMAF) on overall survival in metastatic colorectal cancer. Model 1 utilizes an 
uncorrected rMAF, while model 2 uses rMAF adjusted for copy number alterations. 
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numerator and denominator of their rMAF calculation were not skewing results. The second 
highest allele frequency mutation was chosen as the truncal mutation and used in the copy 
number corrected rMAF calculation for this analysis [Figure 16 – A]. Prognostic differences 
between rMAF >50% and rMAF <50% groups became statistically significant (HR 1.55, 95% CI 
1.01-2.30, P=0.047). A second sensitivity analysis was performed with a replacement of TP53 
whenever it was chosen as the truncal mutation for calculating rMAF, as TP53 is prone to copy 
number losses. In this second sensitivity analysis, prognostic differences between rMAF >50% 
and rMAF <50% groups showed similar trends to all other analyses but were not significant 
(HR 1.48, 95% CI 0.94-2.22, P=0.098) [Figure 16 – B].  
 
Our analysis was also repeated using the pathologist estimate for tumor content in sequenced 
samples. Seven patients with RAS mutations did not have reported tumor content and were 
excluded. Using pathologist estimates of tumor content resulted in 50 patients being classified 
to the rMAF <50% group and 52 patients being classified as rMAF >50%. This redistribution of 
groups resulted in non-significant differences between RAS mutant patients based on allele 
frequency (HR 1.01, 95% CI 0.67-1.52, P=0.95) [Figure 16 –C]. However, if the groups were re-
divided so a similar proportion of patients were in each of the high vs low allele frequency 
groups as were noted in the main rMAF analysis, similar finding to our main analysis were 
noted, with patients having a higher RAS rMAF showing trends towards worse OS (HR 1.54, 
95% CI 0.94-2.38, P=0.098) [Figure 16 – D].  
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Figure 16. Sensitivity analysis of the impact of RAS mutation relative mutant allele frequency 
(rMAF) on overall survival in metastatic colorectal cancer with (A) replacement of RAS as 
truncal mutation whenever found to be truncal, (B) replacement of TP53 as truncal mutation 
whenever found to be truncal, (C) use of pathology assessed tumor content to determine rMAF 
and (D) use of pathology assessed tumor content with an altered rMAF cut point. 
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Relative Mutant Allele Frequency as a Prognostic Marker in MDA CMS46 Cohort 
Of 1877 mCRC patients who had a CMS 46 NGS panel performed, 892 (47.5%) were RAS wild 
type, 85 (4.5%) had low allele frequency RAS mutations (rMAF <50%), and 900 (48.0%) had 
high allele frequency RAS mutations (rMAF >50%). rMAF distribution is displayed in Figure 13 
– C. As seen in Table 8, baseline characteristics were very similar between patients classified 
as low or high RAS rMAF. The only difference noted was that rMAF <50% patients were more 
likely to have left sided tumors than rMAF >50% patients (P=0.0065). Patients with any RAS 
mutation were more likely to be female (P<0.0001), or have a SMAD4 (P<0.0001) or PIK3CA 
mutation (P<0.0001) and less likely to have mucinous/signet ring cell histology (P=0.0060) or 
have a BRAF V600 mutation (P<0.0001) than wild type patients. Unlike the T200 cohort, there 
was no difference in stage at diagnosis between low and high allele frequency RAS mutant 
patients (P=0.68). Copy number information was not available from the CMS 46 panel. 
 
Patients with RAS rMAF >50% had a worse prognosis compared to RAS wild type patients (HR 
1.52, 95% CI 1.35-1.74, P<0.0001) while patients with RAS rMAF <50% did not (HR 1.01, 95% 
CI 0.74-1.39, P=0.95) [Figure 17]. These findings remained constant in a multivariate model 
that controlled for age, gender, stage at diagnosis, histology, primary tumor location, and MSI 
status [Table 9 – Model 1]. Other variables that were significant in the model included having 
stage IV disease at the time of diagnosis (HR 1.45, 95% CI 1.25-1.69, P<0.0001), mucinous or 
signet ring cell histology (HR 1.31, 95% CI 1.06-1.60, P=0.012), and a right sided primary 
tumor location (HR 1.32, 95% CI 1.13-1.54, P=0.0010). When directly comparing RAS mutant 
patients based on allele frequency, RAS rMAF >50% was associated with a worse OS than 
RAS rMAF <50% in both univariate (HR 1.55, 95% CI 1.12-1.88, P=0.0058) and multivariate 
models (HR 1.49, 95% CI 1.04-2.13, P=0.031). The multivariate model included age, gender, 
stage at diagnosis, histology, primary tumor location, and MSI status [Table 9 – Model 2]. 
However, the only co-variate besides allele frequency that remained significant was having 
stage IV disease at the time of diagnosis (HR 1.28, 95% CI 1.06-1.55, P=0.011).  
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In addition to comparing RAS rMAF as defined by a truncal mutation detected on the CMS 46 
panel, we also used the pathologist determined tumor content [Figure 17 – B]. This analysis 
shifted the distribution of groups so that more patients were considered to have low allele 
frequency mutations. Though all patients with RAS mutations had a worse prognosis than wild 
type patients (P<0.0001), there were no differences based on RAS rMAF in this pathologist 
defined groups (HR 1.10, 95% CI 0.91-1.33, P=0.31). As this may have been due to a shifting 
of the group proportions, we repeated the analysis and split the RAS mutant patients so a 
similar proportion of patients to the molecularly defined rMAF were included in the low 
frequency group. Once again, no differences were demonstrated between pathologically 
defined RAS rMAF groups (HR 1.09, 95% CI 0.82-1.44, P=0.58) [Figure 17 – C].  
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Table 8. Baseline characteristics of patients with metastatic colorectal cancer who underwent 
sequencing with a CMS 46 NGS panel stratified by relative mutant allele frequency (rMAF) of 
RAS mutations. 
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Figure 17. Impact of RAS mutation relative mutant allele frequency (rMAF) on overall survival in 
metastatic colorectal cancer patients undergoing NGS with a CMS 46 panel. rMAF was 
calculated (A) using a truncal mutation to define tumor content and (B) using pathologist 
defined tumor content. Even after adjusting the cut point between groups in the pathologically 
defined rMAF analysis (C), prognostic differences were not noted based on rMAF. 
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Table 9. Multivariate models assessing the impact of RAS mutation relative mutant allele 
frequency (rMAF) on overall survival in metastatic colorectal cancer. Model 1 compares RAS 
mutant patients to wild type patients as the reference, while model 2 directly compares RAS 
rMAF groups. 
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Aim 3: To evaluate whether allele frequency can be used as a predictor of 
functional impact. 
Given our findings that RAS rMAF was associated with prognostic differences, we next 
evaluated whether rMAF could be used as a predictive marker of functional significance of any 
gene. This analysis used the MDA T200, MDA CMS 46, cfDNA, and Project Genie cohorts. 
Coding variants from any gene were considered individually in this analysis. 
PODS Functional Annotation 
Based on the MDA PODS functional annotation, inactivating mutations occurred at the highest 
rMAF in all 4 cohorts, while activating mutations were the next highest rMAF category in 3 of 4 
cohorts [Figure 18]. In the MDA CMS 46 cohort, likely benign variants had the second highest 
rMAF. In both the T200 and the cfDNA cohorts, there were statistically significant differences 
between functionally significant (activating/inactivating) variants and likely benign variants that 
were also numerically large (25.2% and 27.1%, respectively), however in the MDA CMS 46 
these differences were not significant and in the Project Genie cohort the difference in rMAF 
was only significant when comparing inactivating to likely benign variants.  The range of 
difference between inactivating variants and likely benign variants was 2.6%-27.1%, with the 
largest range occurring in the cfDNA cohort. Variants that had no functional annotation 
occurred at the lowest rMAF in the MDA CMS 46 and MDA T200 cohorts, while they had the 
second lowest rMAF in the Project Genie cohort. The cfDNA cohort differed from the other 3 
panels as it also had information about synonymous mutations which should have no functional 
impact on a protein. These alterations occurred at the lowest rMAF. 
SIFT/Polyphen Functional Annotation 
In using bioinformatic algorithms to predict functional significance, we saw significantly different 
results based on whether mutations were categorized using SIFT or Polyphen [Figure 19 & 20]. 
The SIFT score consistently showed an association between deleterious variants and a high 
rMAF across all 4 cohorts. Deleterious variants had an rMAF that was statistically higher than  
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Figure 18. Impact of the Precision Oncology Decision Support (PODS) Core defined functional 
significance of a mutation on the relative mutant allele frequency of that mutation. Values 
represent mean +/- 95% confidence interval.  
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Figure 19. Impact of the SIFT score defined functional significance of a mutation on the relative 
mutant allele frequency of that mutation. Values represent mean +/- 95% confidence interval. 
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Figure 20. Impact of the Polyphen score defined functional significance of a mutation on the 
relative mutant allele frequency of that mutation. Values represent mean +/- 95% confidence 
interval. 
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both tolerated and unknown variants. The numerical magnitudes of differences in rMAF were 
however very small (range 4.6%-8.8%), suggesting much of the statistical significance was 
driven by large sample sizes. rMAF differences were largest in the cfDNA group (8.3%). When 
Polyphen was used to categorize variants, there were significant differences across all groups, 
however no individual between group comparisons between benign and pathologic mutations 
were significant except in the Project Genie cohort where all groups had a higher rMAF than 
benign variants. Benign variants had a higher rMAF than probably damaging variants in 2 of 
the 4 cohorts and the range in difference between probably damaging and benign variants was 
-4.2% to 2.2%, with the largest difference occurring in the MDA T200 cohort, however the 
relationship was inverse.  
 
When SIFT/Polyphen were considered together with a merged score, there appeared to be a 
gradual trend of increasing rMAF with higher scores, however variants that received a score of 
0 had the highest rMAF in the MDA CMS 46 and cfDNA cohorts [Figure 21]. Although variants 
with a score of 1, 3, or 4 had higher rMAF than those with a score of 0, these groups had very 
small numbers compared to other comparisons.  Overall, the magnitude of difference between 
variants with a score of 1 and a score of 4 ranged from 3.5% to 9.1%, with the largest 
magnitude of difference occurring in the cfDNA cohort. 
Case Study #1 - BRAF Mutations 
Given that our findings suggested that rMAF differed based on functional classification, we 
decided to choose a well characterized oncogene in CRC to apply this model towards. BRAF 
V600 mutations confer a negative prognosis in patients with mCRC and recent evidence has 
shown that non-V600 variants appear to be of less clinical significance.58, 59 BRAF V600 
mutations occurred at higher rMAFs than non-V600 mutations in the MDA CMS 46 cohort 
(P=0.0038) and cfDNA cohort (P<0.0001), however did not differ among the Project Genie 
(P=0.25) or MDA T200 cohorts (P=0.22) [Figure 22]. Only 23 BRAF mutations were available 
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for assessment in the MDA T200 cohort, however all other cohorts had 145 or more BRAF 
mutations to consider. 
Case Study #2 – rMAF Stratified by Number of Mechanisms of Resistance 
From an evolutionary perspective, the development of resistance often comes at a cost for a 
microorganism or tumor cell and there is little benefit to having multiple mechanisms of 
resistance to the same drug. Using the cfDNA cohort, we aimed to determine whether there 
was a correlation between the number of mechanisms of resistance to anti-EGFR therapy with 
the rMAF of those mechanisms of resistance. As seen in Figure 2.6, a continuous decrease in 
average rMAF of a resistance mechanism was seen as patients developed an increasing 
number of mechanisms of resistance (P<0.0001). If a patient had a single mechanism of 
resistance, the average rMAF of that alteration was 74%, compared to 16% when a patient had 
6+ potential mechanisms of resistance. 
Case Study #3 – rMAF Stratified by RAS Categorization and Functional Significance 
We next sought to evaluate whether the allele frequency of RAS variants differed based on 
RAS categorization (typical, extended, or atypical) or functional significance based on the 
NovellusDx FACT assay. As seen in Figure 24, atypical variants occurred at a lower rMAF than 
typical variants in 3 of the 4 cohorts and the 4th cohort (MDA T200) only had 2 atypical variants 
to evaluate. Extended RAS mutations did not show consistent trends in their relationship to 
typical variants across the 4 cohorts. Figure 25 shows that variants which resulted in signaling 
above that of KRAS exon 2 mutations were of lower rMAF than KRAS exon 2 mutations in 3 
out of 4 cohorts. 
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Figure 21. Impact of the SIFT/Polyphen Merged predicted functional significance of a mutation 
on the relative mutant allele frequency of that mutation. Values represent mean +/- 95% 
confidence interval. 
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Figure 22. Comparison of the relative mutant allele frequency (rMAF) of BRAF V600 and non-
V600 mutations in colorectal cancer. Values represent mean +/- 95% confidence interval. 
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Figure 23. Average relative mutant allele frequency of single nucleotide variants that result in 
resistance to an anti-EGFR agent in colorectal cancer stratified by the number of mechanisms 
of resistance that are present in that patient. Values represent mean +/- 95% confidence 
interval. 
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Figure 24. Average relative mutant allele frequency of RAS variants based on the category of a 
RAS variant (typical vs extended vs atypical). Values represent mean +/- 95% confidence 
interval. 
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Figure 25. Average relative mutant allele frequency of RAS variants based on functional activity 
of the variant. Patients were divided into groups based on whether they had a KRAS exon 2 
mutation or a mutation that resulted in significantly more downstream signaling based on the 
NovellusDx FACT assay. Values represent mean +/- 95% confidence interval.  
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Chapter 4: Discussion 
With recent advancements in genome sequencing capabilities and the exponential decline in 
sequencing costs over the past decade, it is now possible to move precision oncology from the 
bench to the clinic.38 However, the abundance of data now available has expanded our 
awareness of the unanswered questions that arise from these new capabilities. Two particular 
sequencing capacities that have unearthed these questions include the ability to sequence at 
higher sensitivities and the ability to increase coverage over larger regions of the genome. 
Despite significant developments in the molecular characterization of CRC over the past 
decade, RAS mutations still represent one of the most defining molecular characteristics of 
CRC. This body of work aims to determine how NGS can be leveraged to optimally define RAS 
mutant CRC and how to integrate functional characterization into the assessment of unknown 
variants. Given the vast number of novel variants continually discovered, annotation of which 
mutations have clinical significance is of utmost importance. 
Aim 1: Describe the functional and clinical significance of atypical RAS 
mutations 
Given the increasing use of more comprehensive sequencing platforms as part of standard 
care, we need robust mechanisms to annotate variants that are not well described. In 
collaboration with NovellusDx, we identified a comprehensive list of RAS variants that were 
either seen at our institution, Caris Life Sciences, or reported in the literature and performed 
functional annotation while also providing a real-world description of the prevalence of these 
alterations. Although pooled estimates of RAS mutation prevalence from clinical trials are 
available, these cohorts may not be representative of the entire CRC population. Clinical trial 
patients are frequently younger, have better performance status and may have other clinical 
characteristics that make them more likely to seek enrollment on a clinical trial. After pooling 
8609 patients with mCRC from institutional and publicly available cohorts, we identified RAS 
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mutations in 49.3% (95% CI 48.2%-50.4%) of patients. This was statistically lower than the 
55.9% reported by Peeters et al in a pooled analysis from 5 randomized controlled trials and 
highlights the importance of considering real-world data in addition to prospective clinical trials 
(P<0.0001).31 Although there are always inherent biases in retrospective studies, the sheer size 
of our population and the fact that all included panels covered the guideline mandated codons 
strongly supports our point estimate as being one of the most robust available.29  
 
Another important finding from our survey of these 7 databases was that mutations in certain 
codons described in current clinical guidelines are extremely uncommon. For example, out of 
8609 patients, we did not note a single NRAS codon 117 or 146 mutation and only 1 NRAS 
codon 59 mutation was detected. Given that these variants were also not detected in the 
PRIME study which first evaluated extended RAS mutations, there is essentially no evidence to 
support their role as a predictive biomarker and their inclusion in standard of care panels is 
likely not warranted.30 On the contrary, we noted several variants that although uncommon, still 
occurred at a frequency that rivaled many guideline cited variants and were shown to be 
functionally activating. These included KRAS Q22K, KRAS L19F, KRAS D33E, and KRAS 
T50I. Though these variants have not been evaluated as markers of resistance to anti-EGFR 
agents, their functional annotation and recurrent nature would suggest that they should be 
considered pathologic. 
  
Although the NovellusDx FACT assay is a relatively new method for assessing functional 
significance, we have several sources of information that confirm the results obtained. A 
number of the variants included for functional characterization do not have clinical relevance in 
CRC. They were chosen specifically because of their pathogenesis in other diseases. KRAS 
V14I, P34R, T58I, and F156L have all been associated with Noonan syndrome or cardio-facio-
cutaneous syndrome and are well characterized as activating variants that result in decreased 
GTP hydrolysis and varying degrees of increased activity of downstream signaling.63, 64 The 
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NovellusDx assay correctly identified all of these variants as activating. The NRAS A18T 
variant was also included and in melanoma this variant is associated with a good prognosis 
with preliminary in-vitro work suggesting that it is not activating.76 In the Novellus Dx FACT 
assay, this variant was also not deemed activating. We also performed our own in-vitro 
confirmation of 13 variants that represented a mixture of typical, extended, atypical, activating, 
and non-activating variants using a Ba/F3 transformation assay. The NovellusDx FACT and 
Ba/F3 transformation assays were concordant on 13/13 variants. Using a mixture of primary 
literature resources and this in-vitro work, we believe the NovellusDx FACT assay is a robust 
mechanism for assessing the functional relevance of RAS alterations. 
 
One of the hopes in functionally characterizing such a large number of RAS variants was that 
we may be able to find patients with signaling that resembled wild type RAS. This pre-clinical 
information would help identify patients who may benefit from anti-EGFR therapy.  
Unfortunately, while we identified a number of non-activating variants, all of the atypical 
variants in the MDA CMS 46 or T200 cohorts were those that were activating.  Based on the 
prevalence of individual atypical variants, it appears the functionally activating atypical variants 
are the ones that are recurrent in CRC. Importantly, we also noted that a comprehensive 
assessment of the guideline cited mutations did not reveal any lacking non-activating variants. 
This is crucial information as there are repeatedly attempts to identify whether rare mutations in 
that group may still respond to cetuximab/panitumumab. For example, retrospective studies 
suggested that KRAS G13D patients may still respond to anti-EGFR therapy. This lead to the 
ICECREAM trial which was a tremendous effort to prospectively validate whether G13D 
mutants respond to cetuximab, however the trial was negative.36 
 
On the opposite end of the spectrum, we also identified a number of variants that were 
functionally more activating than the well-defined KRAS exon 2 variants. Having one of these 
highly activating mutations was associated with a worse OS than an exon 2 mutation (HR 1.40, 
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P=0.028). Many of these mutations were atypical mutations (KRAS V14I, Q22K, D33E) or were 
mutations in NRAS. Prognostic differences did not remain in multivariate models, however 
highly activating mutations resulted in a larger HR compared to wild type patients than exon 2 
mutations. Though this information is intriguing, it has little clinical utility outside of prognostic 
stratification as all of these patients would be deemed ineligible for anti-EGFR agents.  
 
More interestingly, this analysis led to a direct comparison of KRAS and NRAS mutant patients.  
These two groups have never been shown to have prognostic differences, however we 
demonstrated that NRAS mutations were associated with a worse OS than KRAS mutations. 
As seen in the functional characterization of RAS variants, NRAS alterations were generally 
associated with a larger fold change compared to KRAS alterations. Taken together, these two 
findings suggest that different signaling mechanisms may be responsible for differing behavior. 
NRAS mutations activate the stereotypical MAPK pathway, but are also responsible for 
activating the Rho GTPase Rac1 and Rho A.77, 78 Downstream of these two proteins, the PAK-
1/PDK signaling complex is responsible for activating actin and microtubule cytoskeletons 
leading to increased motility and invasion.79 Other differences between KRAS and NRAS 
include the fact that NRAS mutations are more common at codon 61, while KRAS is 
predominantly codons 12 and 13. Codon 12 and 13 mutations result in RAS being insensitive 
to inactivation by GTPase activating proteins, while codon 61 mutations inhibit intrinsic RAS 
activity. We noted that the poor prognosis of NRAS variants appeared independent of the exon 
mutated. These findings suggest a need to stratify KRAS/NRAS mutant patients as targeted 
therapy combination trials are launched.  
 
The functional characterization of the large number of RAS variants evaluated in our study will 
hopefully serve as an atlas for clinical relevance of atypical variants should they be seen in 
clinical sequencing results. Although we cannot prove that activating variants predict a lack of 
response to therapy, this study presents some of the best available evidence to help stratify 
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atypical variants. By pooling atypical variants together and showing that they have a similar or 
worse prognosis than other RAS mutant CRC and showing that most of the recurrent atypical 
variants result in increased MAPK activity, we provide compelling evidence to consider these 
variants as pathologic. 
Future Directions 
Given the rarity of each of the individual extended and atypical variant characterized, large 
scale collaborations are required to provide clinical annotation and further refine our 
understanding of whether these variants are pathologic. One of the major limitations of our 
study was the small number of atypical and extended mutations with clinical outcomes and 
treatment information. In collaboration with the Mayo Clinic, Caris Life Sciences, and the BC 
Cancer Agency, we will obtain treatment information on patients with atypical variants to try and 
provide further evidence of their clinical impact. Given the fact that some of these patients will 
have had variants that may have been undetected in older versions of RAS testing, we predict 
that there will be some patients who received anti-EGFR therapy that can be evaluated for 
response rates to help establish whether these mutations are predictive.  
Aim 2: Impact of RAS mutant allele frequency on clinical outcomes in mCRC 
Though low allele frequency RAS mutations are being investigated, it is unclear how they 
impact clinical outcomes and assays that are able to detect these mutations have not made 
their way into the clinic.10, 30, 44 In our analysis of RAS mutation rMAF, we noted an association 
of high RAS rMAF with OS in univariate and multivariate models for the CMS 46 cohort (HR 
1.55, P=0.0058), with strong trends also seen in the considerably smaller T200 cohort (HR 
1.59, P=0.075). These results were consistent regardless of whether copy number alterations 
were considered, however RAS mutation rMAF was less able to discriminate a high from low 
risk group when a pathologist’s estimate of tumor content was used in place of a truncal 
mutation. The fact that results were consistent in the T200 cohort with and without copy 
number correction supports the feasibility of using uncorrected rMAF calculations in the CMS46 
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cohort where copy number data was not available and demonstrates that our findings are not 
just highlighting a poor prognosis for patients with RAS amplification or loss of heterozygosity 
for APC or TP53. We also noted that the molecularly defined rMAF was better able to divide 
patients into a low and high risk group than when we used the pathologist defined tumor 
content.54  
 
Our findings suggest that RAS mutation allele frequency may be an important determinant of 
outcome. While this conclusion seems intuitive, RAS mutations have not been shown to be 
prognostic outside of the receipt of anti-EGFR agents. Although we do not have the full 
treatment history for all patients evaluated, the fact that they had a RAS mutation identified on 
their clinically requisitioned assay means they likely did not receive anti-EGFR therapy. Our 
finding that these low rMAF patients have a better prognosis than high rMAF patients despite 
presumed similar treatment is thus novel and requires further exploration. Given that we 
assessed the OS of these patients from the time of their stage IV diagnosis and had over 900 
RAS mutant patients to consider, our findings may be novel due to the power of our study. 
Most prior retrospective studies evaluating RAS as a prognostic marker include patients that 
were on a clinical trial for a single line of therapy.10, 11 These patients were followed for a limited 
time rather than their entire disease course. Many of these studies had only a few hundred 
RAS mutant patients to follow and based on the timing of these studies, they do not include 
high sensitivity assays that provide full coverage of all extended RAS mutations. Given that 
both of our cohorts had excellent long term follow up with a high event rate, had full RAS 
coverage with highly sensitive NGS assays and such large numbers, our results may be 
uncovering a true prognostic impact of RAS mutations that might not be noted in other studies. 
 
The finding that RAS rMAF is prognostic differs from a similar study recently performed by 
Dienstmann et al which suggested that allele frequency of KRAS mutations did not impact OS 
and that allele frequency was not predictive of time to progression in patients with RAS 
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mutations receiving anti-MEK therapy.70 This difference may be explained by the fact that their 
study was smaller (N=322) than our CMS 46 cohort and that they only evaluated KRAS allele 
frequencies as a continuous variable rather than including all RAS mutant patients and using a 
cut-point to create two groups. This difference would suggest that the characteristics of the low 
allele frequency group we defined may be important to consider. As is seen in Table 6 and 8, 
we did not note any consistent difference between RAS mutant patients based on allele 
frequency. However, the T200 cohort demonstrated that RAS mutations with rMAF <50% were 
associated with an earlier stage at diagnosis. While this may suggest patients with a low rMAF 
RAS variant gained it at a different time during their disease course, the fact that there was no 
difference in allele frequency based on whether a primary or metastatic lesion was sampled 
does not support this argument.  
 
The evolutionary context of RAS mutations has been investigated by others and though RAS 
mutations typically occur as early clonal events, others have shown that acquired RAS 
alterations occur at lower allele frequency than the more common early alterations.22, 71, 72 This 
likely explains why such a small proportion of our RAS mutant patients were classified as 
having an rMAF <50%. Most patients will have early truncal RAS mutations, while the low rMAF 
group may be acquired later and behave differently. Siravegna et al have previously shown that 
KRAS clones which develop during anti-EGFR therapy can subsequently disappear following 
withdrawal of treatment and re-challenge can result in responses.73 These acquired mutations 
may not have the clonal stamina to persist as the dominant clone following removal of selective 
pressures. In this setting, the patient’s tumor bulk may behave biologically like a wild-type CRC 
as this is the genotype of the dominant clone. Alternatively, given that we do not have complete 
treatment information for all patients, the reason we are seeing this low allele frequency group 
having a better prognosis may be that these patients were initially thought to be wild type, 
received the benefit from anti-EGFR therapy and subsequently acquired low rMAF RAS 
mutations. 
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In order to help evaluate this possible explanation, we reviewed the cfDNA cohort, which 
though lacking treatment information for most patients, does include at least some patients with 
known prior anti-EGFR therapy. Given current practice patterns regarding cfDNA use, patients 
in this cohort are more likely to be heavily pre-treated and who may have already received anti-
EGFR therapy. In the cfDNA cohort, 236/722 detected RAS variants (32.7%) occurred at an 
rMAF of <50%, significantly more than the patients with tissue based sequencing (P<0.0001). 
This difference may just show the enhanced ability of “liquid biopsies” to sample all parts of a 
tumor concurrently. Alternatively, if these low allele frequency RAS mutations are all acquired, 
this finding may support the notion that most mutations within a tumor mass occur early and 
later acquired mutations are less stable and remain subclonal. This notion is supported by a 
proposed “big bang” model of CRC carcinogenesis in which most of the mutations in a cancer 
are derived early during development and later clonal expansions are less responsible for 
tumor heterogeneity than pre-existing subclonal mixing.74  
 
An important limitation of our study was that patients identified as “low allele frequency” 
mutants represent a range of rMAF values up to 50% and patients with a RAS mutation 
occurring at 0.1% may be very different from a patient with a mutation occurring at 49%. This is 
a major limitation of the two assays used in our MDA cohorts. Both assays used a lower 
threshold for confidently calling mutations in the range of 3-5%. This lower limit of detection is 
important. In the CRYSTAL clinical trial comparing FOLFIRI + cetuximab to FOLFIRI in the first 
line setting, the hazard ratio for PFS was shown to move further in favor of FOLFIRI + 
cetuximab as RAS mutation allele frequency decreased. At a RAS mutant allele frequency of 
0.1%, there was a strong trend towards continued benefit of an anti-EGFR containing regimen 
(HR 0.57, 95% CI 0.33-1.01).75 Another major limitation of our study is the lack of treatment 
annotation and the inability of these cohorts to answer questions surrounding the predictive 
nature of RAS allele frequency. Given that the major clinical implication of RAS mutations is 
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defining whether a certain allele threshold predicts resistance to anti-EGFR agents, this can 
only be defined in a population of patients who has received cetuximab or panitumumab. Our 
work does however provide valuable insights into the biological relevance of allele frequency 
and the importance of considering clonal architecture when interpreting genomic information. 
Future Directions 
Given the importance of assessing ultra-low allele frequency mutations and the need for 
prospective validation of the findings in our retrospective study, we are currently evaluating the 
role of low frequency KRAS/NRAS mutations in the CO.17 clinical trial comparing cetuximab to 
best supportive care in the third line setting.10 This analysis will use a BEAMing digital PCR 
assay. Since the trial includes a best supportive care arm, this analysis will be positioned to 
evaluate the predictive capacity of low allele frequency RAS mutations.  
Aim 3: Utility of allele frequency as a predictor of functional impact. 
With the expansion of sequencing panels to provide broader coverage of the genome, variants 
of unknown significance are becoming an increasing challenge. Even though a gene may be 
actionable, particular mutations may not be. From an evolutionary perspective, alterations that 
result in a survival advantage are likely to be those that drive clonal expansion and tumor 
progression. We hypothesized that more damaging variants may be present at higher allele 
frequencies. Using the clinically annotated PODS database and the SIFT score, we were able 
to demonstrate that pathologic variants were associated with a higher allele frequency. Unlike 
the SIFT score, Polyphen did not appear to differentiate variants of different categories based 
on allele frequency. Both SIFT and Polyphen are useful tools, however bioinformatic 
approaches to functional characterization are often challenged by issues of low specificity and 
multiple concurrent characterizations are ideally required.80, 81 We attempted to use this 
approach by creating a score that merged SIFT and Polyphen scores but this method was also 
hindered by little discrimination between functional groupings. 
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Though we did note statistically significant differences between groups based on functional 
classification, unfortunately outside of the cfDNA cohort most differences were of such small 
magnitude that they would not be clinically useful and statistical significance was likely 
achieved due to the large number of variants utilized in between group comparisons. Even 
when we chose to compare BRAF V600 to non V600 mutations, we had inconsistent findings 
between cohorts that would support the use of rMAF as a determinant of clinical relevance. 
Also arguing against the use of rMAF as a marker in the context of BRAF, was the fact that  
Dienstmann et al demonstrated that BRAF V600E mutations occurred at lower rMAFs than non 
V600 variants in their cohort, showing inconsistent findings and suggesting this metric is not 
readily transferable between platforms.70 Dienstmann et al also did not observe an association 
between allele frequency and PFS in patients on targeted therapies matched to KRAS, BRAF, 
or PIK3CA mutations. Given that Dientsmann and others have shown that driver mutations in 
different genes occur at different allele frequencies, a simple application of rMAF to define 
functional significance may not take into account the evolutionary context of a patient’s cancer 
and the current biologic relevance of a particular clone to the proliferation of a tumor.70, 72 
 
The cfDNA cohort does show some interesting findings however regarding the utility of rMAF. 
The fact that synonymous mutations were shown to occur at the lowest rMAF supports our 
theory of the utility in using rMAF as a marker of functional significance. This cohort also 
showed the largest delta between benign and pathologic variants. Given that the other cohorts 
using the PODS annotation did not show as large of a difference in rMAF, we may be seeing 
evidence that rMAF is associated with the relevance of a mutation to the biologic process 
currently driving proliferation rather than whether a mutation is present anywhere in the total 
tumor mass. cfDNA has a very short half-life of 30 minutes to 2 hours.82 As such, evolutionarily 
quiescent populations are likely to be under represented but may still be present in the total 
tumor mass. These cells may stay in “reserve” until called upon by some evolutionary stressor, 
however the bulk of the cfDNA will be driven by whichever population is rapidly expanding at 
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that moment. This idea that cfDNA may represent a snap shot of the active ecosystem within a 
patient is supported by our second case study that shows the rMAF of a mechanism of 
resistance falls as the patient accumulates more mechanisms of resistance. Figure 23 shows 
that evolutionarily there is no reason for redundancy in mechanisms of resistance and those 
patients who have multiple mechanisms detected, likely have numerous different populations 
competing to become the dominant clone and each of these mechanisms of resistance is likely 
in a private population. However, in the patients that have only a single mechanism of 
resistance, we are seeing that this clone has become dominant as no other independent 
resistance mechanism has developed.  
 
A major limitation in assessing the utility of rMAF in functional characterization is the design of 
the NGS panels used for the cohorts we analyzed. These panels are designed for clinical 
annotation and have an enrichment for pathologic variants that are deemed actionable. As 
such, there are few benign variants detected. Repeating this experiment in patients with whole 
genome or whole exome sequencing may yield different results, however we focused on NGS 
panels as the aim was determine whether rMAF could be used as a clinical tool and 
exome/genome sequencing is not a clinical reality for most patients. Panel design may also 
explain why the cfDNA showed the largest variance in rMAF based on functional 
characteristics. The cfDNA assay used in our study has a lower limit of detection of 0.1%.45 
Given that the NGS panels used in the other cohorts have thresholds of ~5%, cfDNA may be 
picking up more truly low allele frequency mutations that are missed by the assays in the tissue 
cohorts.  
Future Directions 
Though we failed to demonstrate the utility of using rMAF as a tool for defining the functional 
relevance of a mutation, the findings in our cfDNA cohort are striking and demonstrate potential 
clinical utility. There have already been a number of studies demonstrating the utility in tracking 
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clonal evolution with cfDNA to integrate this information into therapeutic decisions such as with 
anti-EGFR re-challenge or tracking for tumor recurrence. Current work by our group is 
assessing how to incorporate cfDNA assessments into clinical care and I am analyzing a cohort 
of patients with serial blood draws to demonstrate how useful following clonal dynamics is on a 
larger scale. Most current reports tracking serial cfDNA outside of surveillance studies have not 
yet demonstrated at what frequency clonal architecture changes of clinical significance occur 
on serial samplings. Of particular interest, I will be evaluating whether mechanisms of 
resistance detected on cfDNA are stable over time and the kinetics of how these mechanisms 
may be lost. 
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Conclusions 
We present a comprehensive functional annotation of RAS mutations that will hopefully help 
guide clinicians when these variants are found during clinical sequencing. Our results show that 
many recurrent atypical variants are functionally activating and associated with a poor 
prognosis. These findings support the inclusion of all RAS exons in clinical sequencing panels 
and demonstrate the need for a personalized approach to handling variants of unknown 
significance. Though rMAF was not useful in characterizing variants as functional vs benign, 
our findings that RAS rMAF is associated with prognosis suggests allele frequency may be 
useful information to include in standard clinical reports. The ability of this work to study rare 
variants using pre-existing databases and many publicly available data sets supports open 
access to sequencing results and de-identified clinical data to optimize patient outcomes in rare 
subgroups. As we move into evaluating therapies in smaller subgroups of patients, these 
collaborative large scale projects will be key to ensuring our decisions are based on best 
available evidence.    
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